SCHILKE TOBIN (CFO) received a stock award from REVANCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/5/2025ACC: 0000950170-25-014824
Officer· CFO
Since Nov 2018
+6.89K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
6.89K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+6.89K
Price / share
—
Trade value
—
% of position
3.5%
2/3/2025
194.67K→201.55K
Total
Net shares
+6.89K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/3/2025 | A · Award | +6.89K | — | — | 3.5% | 194.67K | 201.55K |
| Total | +6.89K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported